SEC Tracker
Get the app
FBIO · XBRL financial data

Fortress Biotech financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (FBIO's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue34,75219,946*13,03014,89614,62915,120*13,13916,41317,63116,079*16,03818,718
Cost of goods and services sold6,4296,015*6,8166,5415,2852,237*4,7904,9395,7555,440*6,2186,143
Research and development20,34814,076*24,83912,6719,446———————
Selling, general and administrative21,73322,612*17,94120,82321,99326,864*25,66338,75717,41514,730*15,89320,807
Operating income (loss)(13,758)(19,614)*(36,566)(27,788)(22,095)(23,835)*(22,317)(36,473)(6,811)(4,789)*(7,739)(10,006)
Interest income547707*833734589526*490622736637*5701,581
Interest expense2,5342,060*2,6022,1226,2092,594*2,8052,5182,7422,041*3,3681,476
Other income (expense)620(1,354)*(21)2821,071(16)*(12)(62)17,672(21)*1,04210,741
Income tax expense (benefit)141379*0069336*0026(816)*5,132320
Net income (loss)(5,045)(9,279)*(15,417)(10,948)(12,867)(6,765)*(10,584)15,4865,850(3,937)*110,373(468)
Earnings per share, basic USD per share(0.94)—(1.03)(0.73)(0.76)—(0.48)0.500.13—3.44(0.08)
Earnings per share, diluted USD per share(0.94)—(1.04)(0.73)(0.76)—(0.48)0.450.11—2.82(0.08)
Weighted average shares, basic thousands of shares7,499—17,15218,31719,697—26,45026,87927,24430,991*31,54131,791
Weighted average shares, diluted thousands of shares7,499—17,15218,31719,697—26,45029,82433,101—38,41331,791

Balance sheet

CSV

Fiscal quarters (FBIO's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents72,30780,92783,77476,20158,85357,26391,33974,38686,21879,381255,841196,576
Accounts receivable7,98915,2229,79910,46510,67110,23118,02515,64417,98329,78324,99236,246
Inventory11,02410,20610,5809,68711,78814,43112,49612,85211,8189,6249,2928,156
Prepaid and other current assets6,34110,50012,0714,6492,5837,1104,7346,9562,3424,8954,8394,022
Total current assets97,826117,022116,548103,43586,27890,371126,903110,396118,503123,841295,480245,506
Property and equipment, net6,8546,5056,1283,5463,4033,2602,7962,7042,6112,5192,4262,412
Right-of-use asset17,50716,99016,46214,62614,15213,86113,30312,81712,32112,30211,82211,357
Total assets150,549167,526164,645145,685127,085144,223178,071159,895181,407185,548356,874316,715
Accounts payable44,73134,81041,80337,95734,03031,63627,81820,19018,77114,23814,13911,856
Accrued liabilities81,40673,56276,37968,92164,49965,50166,28648,57645,17147,12592,98649,325
Total current liabilities97,35184,90887,69675,54370,30571,39973,67457,52154,06749,744103,39362,018
Lease liability, non-current18,94418,28217,61915,93415,29214,75013,82013,30312,76512,67212,02811,468
Total liabilities163,792165,939168,582160,283139,823145,867145,585122,512116,222123,365154,500110,629
Accumulated deficit(685,591)(694,870)(710,287)(721,235)(734,102)(740,867)(751,451)(735,965)(730,115)(734,052)(623,679)(624,147)
Total stockholders' equity16,67422,54423,02517,87721,15822,73722,25043,92455,86249,873162,208164,140
Total liabilities and equity150,549167,526164,645145,685127,085144,223178,071159,895181,407185,548356,874316,715
Common shares outstanding (cover page) thousands of shares8,93815,09319,37522,58727,58527,90929,55529,75331,00531,36433,18733,311

Cash flows

CSV

Fiscal quarters (FBIO's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(5,045)(9,279)*(15,417)(10,948)(12,867)(6,765)*(10,584)15,4865,850(3,937)*110,373(468)
Stock-based compensation4,377*3,704*4,8574,999*6,573*16,190*6,28916,793*3,198*2,459*1,7562,878*
Net cash from operating activities(16,779)*(34,935)*(25,387)(21,838)*(20,059)*(12,907)*(19,563)(27,560)*(6,110)*(12,544)*203,851(59,277)*
Purchases of property and equipment1*28*——0*0*——————
Net cash from investing activities4,999*(63)*00*0*(15,000)*1,1656,086*2,870*0*0(79)*
Proceeds from issuing common stock888*(15)*8941,932*568*340*1,009(1)*0*0*0—
Dividends paid185*180*176176*176*166*166166*166*166*0—
Net cash from financing activities(2,685)*43,618*27,85914,265*2,711*25,806*52,1424,521*15,072*5,707*(27,391)91*
Net change in cash(14,465)*8,620*2,472(7,573)*(17,348)*(2,101)*33,744(16,953)*11,832*(6,837)*176,460(59,265)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Fortress Biotech196,57618,718(59,277)*33.3M3.3 quarters 10-QJun 30, 2026
Actinium Pharmaceuticals36,47335,000(5,179)*31.4M7.0 quarters 10-QJun 30, 2026
Lite Strategy5,706not reported(1,164)*30.4M4.9 quarters 10-KJun 30, 2026
Acumen Pharmaceuticals53,075not reported(26,653)*72.3M3.4 quarters 10-QSep 30, 2026
Actuate Therapeutics4,426not reported(4,405)*24.0M1.0 quarters 10-QJun 30, 2026
Opus Genetics88,812755(11,950)*83.2M7.4 quarters 10-QJun 30, 2026
Precision Biosciences81,6980(15,132)*27.9M6.1 quarters 10-QSep 30, 2026
CervoMed22,4630(6,918)*15.1M3.6 quarters 10-QJun 30, 2026
Atara Biotherapeutics3,221630(3,338)*10.0M3.0 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.